Share

Centri’s Christopher Mora Featured on Healthcare Brew – Kenvue’s IPO Success

Centri’s Christopher Mora, Partner and SEC & Capital Markets Practice Leader, is featured in a Healthcare Brew article about Kenvue’s IPO.  With the strong brands that make up Kenvue (such as Tylenol, Band-Aid, and Neutrogena), the IPO was able to raise $3.8 billion, making it one of the largest IPOs since 2021 despite challenging market conditions.

Even with uncertainty in the capital markets, there are steps you can take now to make sure you are prepared when market conditions are more favorable.  Our IPO advisory consultants can provide a wide variety of advisory services, including:

• Comprehensive project management, best practices, and strategies
• Audit support as you prepare for PCAOB-compliant audits
• Valuation services, like 409A analyses, cheap stock, deferred compensation expense calculations, and other fair value considerations
• Assistance converting from one accounting basis to another (e.g., conversions from home country GAAP to U.S. GAAP or International Financial Reporting Standards)
• Assistance with the preparation of compliant interim information
• Preparation of technical accounting memorandums, including earnings per share considerations and segment- or entity-wide disclosures
• Guidance on any required organizational or process adjustments

Contact us to get started today.

Christopher Mora

Chief Revenue Officer & Partner | SEC & Capital Markets Practice Leader

Christopher is the Chief Revenue Officer & Partner at Centri Business Consulting. He is the leader of the firm’s SEC Financial Reporting and Capital Markets Practice and specializes in the delivery of capital market readiness...